Access Denied? The Unintended Consequences of Pending Drug Pricing Rules
The government of Canada now plans to bring into force new federal drug pricing regulations on 1 July 2022. We do not take issue with the goal of medication affordability, which is vital in healthcare the world over. Our concern is that the new guidelines are being implemented without due considerat...
Main Authors: | Alan Kaplan, David J. Stewart, Gerald Batist, Silvana Spadafora, Sandeep Sehdev, Shaun G. Goodman |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/29/4/204 |
Similar Items
-
Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action
by: Sandeep Sehdev, et al.
Published: (2024-03-01) -
Evaluation of potential drug interactions in hospitalized pediatric oncology patients
by: Emanuella de Souza Ribeiro, et al.
Published: (2021-02-01) -
Relevant aspects of toxicocardiology
by: Yu.I. Markov
Published: (2022-04-01) -
New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices
by: David J. Stewart, et al.
Published: (2024-04-01) -
Pharmacotherapy of Oncological Diseases: Search for New Drugs and Approaches
by: M. V. Belova
Published: (2023-05-01)